{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:09:46Z","timestamp":1788016186518,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["23K15911"],"award-info":[{"award-number":["23K15911"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["24K12767"],"award-info":[{"award-number":["24K12767"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study aimed to investigate changes in choroidal thickness using widefield optical coherence tomography after anti\u2013vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We examined 69 patients with unilateral neovascular AMD. All patients underwent three monthly intravitreal injections of anti-VEGF agents. Widefield choroidal thickness within an 18-mm circular grid centered on the fovea, subdivided into nine areas, was evaluated at baseline and at 3 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Forty-two and 27 patients were classified into the AMD and pachychoroid neovasculopathy (PNV) groups, respectively. At 3 months, the treated eyes in both groups showed significantly and extensively reduced choroidal thickness (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01 for all areas). The untreated fellow eyes in the PNV group also showed decreased choroidal thickness at 3 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05 for all areas). Complete retinal fluid resolution was significantly associated with a greater decrease ratio of choroidal thickness in the PNV group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05 for all areas).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Anti-VEGF therapy for neovascular AMD led to extensively decreased choroidal thickness. In patients with PNV, a greater decrease in overall choroidal thickness appeared to be associated with more effective resolution of retinal fluid. Observation of widefield choroidal thickness may be important for the management of neovascular AMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004651","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T21:03:14Z","timestamp":1756846994000},"page":"98-107","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["CHANGES IN WIDEFIELD CHOROIDAL THICKNESS AFTER ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"46","author":[{"given":"Sorako","family":"Wakugawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Imanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choyu","family":"Kuroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Miyara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Maehira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-4386","authenticated-orcid":false,"given":"Hideki","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251218","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"R2-20251218","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajo.2008.05.032","article-title":"Enhanced depth imaging spectral-domain optical coherence tomography","volume":"146","author":"Spaide","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R3-20251218","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1167\/iovs.09-4383","article-title":"Choroidal thickness in healthy Japanese subjects","volume":"51","author":"Ikuno","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20251218","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00417-011-1620-1","article-title":"Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"249","author":"Koizumi","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R5-20251218","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ophtha.2010.09.012","article-title":"Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration","volume":"118","author":"Chung","year":"2011","journal-title":"Ophthalmology"},{"key":"R6-20251218","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/IAE.0000000000000086","article-title":"Subfoveal choroidal thickness in retinal angiomatous proliferation","volume":"34","author":"Yamazaki","year":"2014","journal-title":"Retina"},{"key":"R7-20251218","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00417-015-3260-3","article-title":"Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration","volume":"254","author":"Yun","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R8-20251218","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","article-title":"Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results","volume":"119","author":"Yamazaki","year":"2012","journal-title":"Ophthalmology"},{"key":"R9-20251218","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajo.2014.12.025","article-title":"Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration","volume":"159","author":"Koizumi","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R10-20251218","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","article-title":"Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results","volume":"123","author":"Koizumi","year":"2016","journal-title":"Ophthalmology"},{"key":"R11-20251218","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00417-021-05517-1","article-title":"Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study","volume":"260","author":"Tamashiro","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R12-20251218","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/IAE.0b013e3182680a66","article-title":"Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration","volume":"32","author":"Fung","year":"2012","journal-title":"Retina"},{"key":"R13-20251218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","article-title":"Pachychoroid neovasculopathy","volume":"35","author":"Pang","year":"2015","journal-title":"Retina"},{"key":"R14-20251218","doi-asserted-by":"crossref","first-page":"16204","DOI":"10.1038\/srep16204","article-title":"Pachychoroid neovasculopathy and age-related macular degeneration","volume":"5","author":"Miyake","year":"2015","journal-title":"Sci Rep"},{"key":"R15-20251218","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1167\/iovs.17-22144","article-title":"Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovasculopathy","volume":"59","author":"Padr\u00f3n-P\u00e9rez","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-20251218","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"R17-20251218","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","article-title":"Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy","volume":"15","author":"Spaide","year":"1995","journal-title":"Retina"},{"key":"R18-20251218","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","article-title":"Retinal angiomatous proliferation in age-related macular degeneration","volume":"21","author":"Yannuzzi","year":"2001","journal-title":"Retina"},{"key":"R19-20251218","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.oret.2017.08.016","article-title":"Pachychoroid geographic atrophy: clinical and genetic characteristics","volume":"2","author":"Takahashi","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R20-20251218","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10384-018-0562-0","article-title":"Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration","volume":"62","author":"Matsumoto","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"R21-20251218","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1007\/s00417-024-06578-8","article-title":"One-year choroidal thickness changes after photodynamic therapy for central serous chorioretinopathy evaluated by widefield optical coherence tomography","volume":"262","author":"Sawaguchi","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R22-20251218","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.3390\/jcm12165364","article-title":"Differences in central and peripheral choroidal thickness among the subtypes of age-related macular degeneration in an Asian population","volume":"12","author":"Fukuda","year":"2023","journal-title":"J Clin Med"},{"key":"R23-20251218","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","article-title":"Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan","volume":"13","author":"Mukai","year":"2023","journal-title":"Sci Rep"},{"key":"R24-20251218","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"R25-20251218","first-page":"H1054","article-title":"VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells","volume":"274","author":"Hood","year":"1998","journal-title":"Am J Physiol"},{"key":"R26-20251218","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3390\/jcm13061608","article-title":"Wide-field choroidal thickness analysis after half-fluence photodynamic therapy combined with intravitreal aflibercept injection in pachychoroid neovasculopathy","volume":"13","author":"Fukuda","year":"2024","journal-title":"J Clin Med"},{"key":"R27-20251218","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/IAE.0b013e31822c28d6","article-title":"Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration","volume":"32","author":"Hosseini","year":"2012","journal-title":"Retina"},{"key":"R28-20251218","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"R29-20251218","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R30-20251218","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41433-024-03253-4","article-title":"Pachychoroid disease: review and update","volume":"39","author":"Cheung","year":"2025","journal-title":"Eye (Lond)"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:19Z","timestamp":1766073619000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004651","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}